Home » Stocks » LUNG

Pulmonx Corporation (LUNG)

Stock Price: $65.86 USD 2.92 (4.64%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 2.34B
Revenue (ttm) 31.74M
Net Income (ttm) -28.08M
Shares Out 32.47M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $65.86
Previous Close $62.94
Change ($) 2.92
Change (%) 4.64%
Day's Open 62.50
Day's Range 59.33 - 66.13
Day's Volume 86,132
52-Week Range 39.31 - 69.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering Georgia Garinois-Melenikiotou and Thomas W. Burns...

GlobeNewsWire - 1 month ago

The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment...

GlobeNewsWire - 2 months ago

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor confer...

GlobeNewsWire - 2 months ago

Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from He...

GlobeNewsWire - 3 months ago

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that ...

Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: ESI, SELB, AVO, CCXX, IMNM
GlobeNewsWire - 3 months ago

REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatme...

Seeking Alpha - 3 months ago

Pulmonx: Assessing The IPO

Market Watch - 3 months ago

Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The d...

Market Watch - 3 months ago

Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18.

GlobeNewsWire - 3 months ago

REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common s...

Market Watch - 3 months ago

Pulmonx, a maker of treatments for lung diseases including emphysema, upsized its planned initial public offering on Wednesday and raised the proposed price range, saying in a regulatory filin...

About LUNG

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also prov... [Read more...]

Industry
Surgical and Medical Instrument Manufacturing
IPO Date
Oct 1, 2020
CEO
Glendon E. French
Employees
180
Stock Exchange
NASDAQ
Ticker Symbol
LUNG
Full Company Profile

Financial Performance

In 2019, Pulmonx's revenue was $32.60 million, an increase of 62.94% compared to the previous year's $20.00 million. Losses were -$20.70 million, 12.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Pulmonx stock is "Buy." The 12-month stock price forecast is 53.80, which is a decrease of -18.31% from the latest price.

Price Target
$53.80
(-18.31% downside)
Analyst Consensus: Buy